New findings from the University of Glasgow offer a key that will help doctors and the pharmaceutical industry more effectively target the weaknesses of what has been, up till now, one of the most treatment-resistant and lethal cancers.
New findings from the University of Glasgow offer a key that will help doctors and the pharmaceutical industry more effectively target the weaknesses of what has been, up till now, one of the most treatment-resistant and lethal cancers.